Distinct Transcript-Level Expression Profiles and Unique Alternative Splicing in Inflammatory Myopathies.


Journal

ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025

Informations de publication

Date de publication:
27 Jul 2024
Historique:
revised: 18 06 2024
received: 02 04 2024
accepted: 28 06 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: aheadofprint

Résumé

The pathogenesis of inflammatory myopathies is poorly understood and there is a need to dissect the transcriptome in more granular ways beyond gene expression. We used a set of muscle RNA-sequencing data from different myositis subtypes grouped by their specific autoantibodies (n = 152). We quantified annotated RNA transcripts for each myositis subtype and identified uniquely expressed RNA as well as transcriptional similarities among myositis types. In addition, we quantified event-based alternative splicing with predicted protein changes. And finally, we searched for cryptic exons. We saw considerable overlap in RNA expression among subtypes. In addition, MADCAM1 was previously shown to be uniquely expressed in Mi-2 myositis; we discovered it was two noncanonical transcripts that predominantly contributed to the observed increased expression. At the transcriptional level, dermatomyositis subtypes were least similar to inclusion body myositis (IBM) or Jo1, followed by HMGCR, then SRP and other dermatomyositis subtype. Additionally, we discovered many alternative splicing events that were unique by myositis subgroup, including events in muscle dystrophy genes and one event in SRP72, which was seen uniquely in SRP myositis. Finally, we looked for previously reported cryptic exons in IBM and did not find them. The large degree of transcriptional overlap among myositis subtypes reinforces the need to use disease (in addition to healthy) controls to find unique features of autoimmune disease. Unique alterations in the transcriptome that are seen in one myositis subtype and not others advance our understanding of distinct disease pathology.

Identifiants

pubmed: 39073022
doi: 10.1002/acr2.11724
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIAMS NIH HHS
ID : K08AR082939
Pays : United States

Informations de copyright

© 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Betteridge Z, McHugh N. Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280:8−23.
Casal‐Dominguez M, Pinal‐Fernandez I, Pak K, et al. Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for idiopathic inflammatory myopathies in patients with myositis‐specific autoantibodies. Arthritis Rheumatol 2022;74:508−517.
Damoiseaux J, Vulsteke JB, Tseng CW, et al. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono‐ and multispecific immunoassays. Autoimmun Rev 2019;18:293−305.
Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116−123.
Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231−249.
Pinal‐Fernandez I, Casal‐Dominguez M, Derfoul A, et al. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis 2020;79:1234−1242.
Amici DR, Pinal‐Fernandez I, Christopher‐Stine L, et al. A network of core and subtype‐specific gene expression programs in myositis. Acta Neuropathol 2021;142:887−898.
Pinal‐Fernandez I, Casal‐Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology 2019;93:e1193−e1204.
Wang Y, Liu J, Huang BO, et al. Mechanism of alternative splicing and its regulation. Biomed Rep 2015;3:152−158.
Olsson E, Honeth G, Bendahl PO, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011;11:418.
Love JE, Hayden EJ, Rohn TT. Alternative splicing in Alzheimer's disease. J Parkinsons Dis Alzheimers Dis 2015;2:6.
Ren P, Lu L, Cai S, et al. Alternative splicing: a new cause and potential therapeutic target in autoimmune disease. Front Immunol 2021;12:713540.
Ibáñez‐Costa A, Perez‐Sanchez C, Patiño‐Trives AM, et al. Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti‐TNF therapy. Ann Rheum Dis 2022;81:56−67.
Andrews S. FastQC: a quality control tool for high throughput sequence data. Accessed XX. XX.
Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA‐seq aligner. Bioinformatics 2013;29:15−21.
Wang L, Wang S, Li W. RSeQC: quality control of RNA‐seq experiments. Bioinformatics 2012;28:2184−2185.
Patro R, Duggal G, Love MI, et al. Salmon provides fast and bias‐aware quantification of transcript expression. Nat Methods 2017;14:417−419.
Zhu A, Srivastava A, Ibrahim JG, et al. Nonparametric expression analysis using inferential replicate counts. Nucleic Acids Res 2019;47:e105.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Series B Stat Methodol 1995;57:289−300.
Najjar R, Mustelin T. Prediction of alternative pre‐mRNA splicing outcomes. Sci Rep 2023;13:20000.
Quinlan, AR. BEDTools: the Swiss‐Army tool for genome feature analysis. Curr Protoc Bioinformatics 2014;47:11.12.1−34.
Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol 2011;29:24−26.
Zhang K, Da J, Liu X, et al. Downregulated expression of RIPOR3 correlated with immune infiltrates predicts poor prognosis in oral tongue cancer. Med Sci Monit 2022;28:e935055.
Pinal‐Fernandez I, Milisenda JC, Pak K, et al. Transcriptional derepression of CHD4/NuRD‐regulated genes in the muscle of patients with dermatomyositis and anti‐Mi2 autoantibodies. Ann Rheum Dis 2023;82:1091−1097.
Britson KA, Ling JP, Braunstein KE, et al. Loss of TDP‐43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med 2022;14:eabi9196.
Okada N, Mimori T, Mukai R, et al. Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol 1987;138:3219−3223.
Satoh T, Okano T, Matsui T, et al. Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol 2005;32:1727−1733.
Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990;33:1361−1370.
Ng B, Yang F, Huston DP, et al. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 2004;114:1463−1470.
Gonzalez‐Quereda L, Gallardo E, Töpf A, et al. A new mutation of the SCGA gene is the cause of a late onset mild phenotype limb girdle muscular dystrophy type 2D with axial involvement. Neuromuscul Disord 2018;28:633−638.

Auteurs

Rayan Najjar (R)

University of Washington, Seattle, Washington.

Hugh Alessi (H)

University of Washington, Seattle, Washington.

Iago Pinal-Fernandez (I)

National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, Maryland.

Andrew L Mammen (AL)

National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, Maryland.

Tomas Mustelin (T)

University of Washington, Seattle, Washington.

Classifications MeSH